TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20636249

Group type: EXPERIMENTAL
Intervention: Brief individual cognitive behavioral counseling comprising three weekly 1 hour sessions (n = 33)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard care (n = 34)
Number of subjects: 67
Study: 18829240

Group type: EXPERIMENTAL
Intervention: Stent graft
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bare stent
Number of subjects: 25
Study: 16606389

Group type: EXPERIMENTAL
Intervention: Transvenous lead removal using locking stylets and sheaths
Number of subjects: 53

Group type: COMPARATOR
Intervention: Primary lead removal using sternotomy and extracorporeal circulation (ECC)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Transvenous lead removal
Number of subjects: 53

Group type: COMPARATOR
Intervention: Primary lead removal using ECC
Number of subjects: 53
Study: 12538506

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 13647

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily)
Number of subjects: 13647

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13647
Study: 10664941

Group type: EXPERIMENTAL
Intervention: AutoCyte PREP liquid‐based, thin‐layer preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Pap smear
Number of subjects: 0
Study: 8793608

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole s.i.d. for 10 days and 20 mg nifedipine sustained release (SR) b.i.d. from day 6 to 10
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20 mg nifedipine SR b.i.d. for 5 days (reference period)
Number of subjects: 24
Study: 1503072

Group type: EXPERIMENTAL
Intervention: Milk supplement
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 371
Study: 3930248

Group type: EXPERIMENTAL
Intervention: Nitroglycerin 0.5 mg sublingually
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30522768

Group type: EXPERIMENTAL
Intervention: Hypoxia (11% oxygen balanced in nitrogen)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypoxemia (carbon monoxide plus normoxia)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia (room air)
Number of subjects: 8
Study: 28801149

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral hypnosis (placebo)
Number of subjects: 60
Study: 27605491

Group type: EXPERIMENTAL
Intervention: LP 532-nm laser alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: LP 532-nm laser in combination with LP 1064-nm laser
Number of subjects: 22
Study: 24298995

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 339
Study: 22168810

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study: 20389213

Group type: EXPERIMENTAL
Intervention: House flap
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rhomboid flap
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Y-V anoplasty
Number of subjects: 60
Study: 17389658

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once-weekly (QW)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice-weekly (BIW)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 16310609

Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU QD SC
Number of subjects: 129

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) 5,000 IU BID SC
Number of subjects: 129
Study: 12171433

Group type: EXPERIMENTAL
Intervention: 250 mg of HCA for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 0
Study: 10615818

Group type: EXPERIMENTAL
Intervention: Transmission system (telematic data transmission)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Classical treatment
Number of subjects: 17
Study: 7777424

Group type: EXPERIMENTAL
Intervention: CPI Endotak lead system
Number of subjects: 307
Study: 2106732

Group type: EXPERIMENTAL
Intervention: Cefonicid (a cephalosporin with a long half-life)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mezlocillin (a broad-spectrum ureidopenicillin)
Number of subjects: 0
Study: 210379

Group type: EXPERIMENTAL
Intervention: Neomycin-polymyxin irrigant administered through closed urinary catheters
Number of subjects: 187

Group type: COMPARATOR
Intervention: No irrigation (control group)
Number of subjects: 187
Study: 31400271

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 µg/kg initial dose and then 0.2 µg/kg/h for 10 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam-Fentanyl (0.05 mg/kg fentanyl at a dose of 1 µg/kg for 10 minutes)
Number of subjects: 60
Study: 29171646

Group type: EXPERIMENTAL
Intervention: slow rocuronium injection (0.6 mg/kg IV) with remifentanil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: fast rocuronium injection with remifentanil
Number of subjects: 120

Group type: COMPARATOR
Intervention: slow rocuronium injection with saline
Number of subjects: 120

Group type: COMPARATOR
Intervention: fast rocuronium injection with saline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: slow rocuronium injection with remifentanil
Number of subjects: 120
Study: 24845600

Group type: EXPERIMENTAL
Intervention: Electrocortical Stimulation (ECS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: high gamma electrocorticography (hgECoG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging (fMRI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Post-surgical outcomes
Number of subjects: 23
Study: 23836616

Group type: EXPERIMENTAL
Intervention: Systematic smoking ascertainment and default provision of behavioural support and cessation pharmacotherapy during hospital stay; follow-up and referral to community services after discharge.
Number of subjects: 493

Group type: COMPARATOR
Intervention: Usual care comprising cessation support delivered at the initiative and discretion of clinical staff.
Number of subjects: 493
Study: 21745115

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bipolar transurethral resection of the prostate (TURP)
Number of subjects: 60
Study: 19915222

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 5362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5362
Study: 17323591

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 12092

Group type: COMPARATOR
Intervention: Standard therapy (placebo or unfractionated heparin)
Number of subjects: 12092
Study: 12641862

Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment
Number of subjects: 2288

Group type: EXPERIMENTAL
Intervention: Oseltamivir on formulary
Number of subjects: 2288
Study: 11052557

Group type: EXPERIMENTAL
Intervention: Pill organizer
Number of subjects: 481

Group type: COMPARATOR
Intervention: No organizer
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Blister packs
Number of subjects: 481

Group type: COMPARATOR
Intervention: Pill organizers
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Active supplements
Number of subjects: 481

Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 481
Study: 9110907

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Melphalan, prednisone, and colchicine
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Reduction in serum or urine monoclonal protein at 12 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: No reduction in serum or urine monoclonal protein at 12 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Overall survival of patients
Number of subjects: 220
Study: 8257409

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-dose naltrexone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 4007041

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 59

Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 59
Study: 31095810

Group type: EXPERIMENTAL
Intervention: Diluted single-phase (DS; 1.6 ml/s)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diluted biphasic (DB; 9 ml @ 3.3 ml/s, 29 ml @ 1.4 ml/s)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patient-tailored protocol using linear prediction (DT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nondiluted single-phase (NS; 1.6 ml/s)
Number of subjects: 40
Study: 29098260

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided superior laryngeal nerve block and cricothyroid membrane puncture (Group U)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Anatomical location group (Group A)
Number of subjects: 30
Study: 26716735

Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No intra-arterial treatment (Control)
Number of subjects: 500
Study: 24357015

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study: 22978083

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lithium (control group)
Number of subjects: 60
Study: 20538417

Group type: EXPERIMENTAL
Intervention: Structural Ecosystems Therapy (SET)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Health Group (HG)
Number of subjects: 126
Study: 17944770

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg intravenous infusion
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 16127404

Group type: EXPERIMENTAL
Intervention: Grapefruit consumption
Number of subjects: 58

Group type: COMPARATOR
Intervention: Diseased control group
Number of subjects: 58
Study: 11802224

Group type: EXPERIMENTAL
Intervention: Multidisciplinary interventions (psychosocial strategies, nursing approaches, psychotropic medications, management of pain)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Early intervention group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Late intervention group
Number of subjects: 99
Study: 10425672

Group type: EXPERIMENTAL
Intervention: Telephone support calls by social workers (professional team)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Telephone support calls by secretarial staff (nonprofessional team)
Number of subjects: 93
Study: 7585237

Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Visual function tests
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: LOCS III
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CCD
Number of subjects: 73
Study: 2266237

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 6998239

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 31418950

Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 28319673

Group type: EXPERIMENTAL
Intervention: Montelukast for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 58
Study: 26012297

Group type: EXPERIMENTAL
Intervention: Combination therapy with azelastine and fluticasone propionate
Number of subjects: 162

Group type: COMPARATOR
Intervention: Nasal corticosteroids monotherapy
Number of subjects: 162
Study: 24228935

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20237778

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral TKA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unilateral TKA
Number of subjects: 40
Study: 20031582

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Candidate gene analysis of 23 genes
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Whole-genome analysis
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Age and gender influence
Number of subjects: 5745
Study: 18757661

Group type: EXPERIMENTAL
Intervention: Burch colposuspension or pubovaginal sling surgery for SUI in older women (≥65 years)
Number of subjects: 655
Study: 15316717

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 4 weeks
Number of subjects: 18
Study: 12140020

Group type: EXPERIMENTAL
Intervention: Deep lamellar keratoplasty (DLKP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PKP)
Number of subjects: 24
Study: 10190777

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (60+/‐4% of maximal heart rate)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High intensity exercise (84+/‐4% of maximal heart rate)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study: 7802268

Group type: EXPERIMENTAL
Intervention: Self-inflating bulb (SIB) used with blind insertion of ETC (Group 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Self-inflating bulb (SIB) used with direct vision placement of ETC (Group 2)
Number of subjects: 46
Study: 2103531

Group type: EXPERIMENTAL
Intervention: Bendazac-lysine salt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7387336

Group type: EXPERIMENTAL
Intervention: Synthetic human beta-endorphin infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Beta-endorphin treatment
Number of subjects: 18
Study: 30180860

Group type: EXPERIMENTAL
Intervention: PrEP delivery integrated in HIV care clinics; includes staff training, streamlined access to PrEP commodities, and ongoing technical assistance.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PrEP service delivery conducted by clinic staff with no additional resources from the project.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Implementation science evaluation using the RE-AIM framework.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stepped-wedge, cluster-randomized trial design.
Number of subjects: 24
Study: 26548963

Group type: EXPERIMENTAL
Intervention: Usual nonoperative care for symptomatic LDH
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Complete initial resolution of leg pain
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Complete initial resolution of LBP
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Complete leg pain resolution
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Posterolateral herniation location
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Joint problems
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 478
Study: 24460405

Group type: EXPERIMENTAL
Intervention: Music adapted to brain rhythm anomalies associated with psychoticism
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard classical music
Number of subjects: 50
Study: 23059574

Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate (Novamin SHY NM) dentifrice
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pepsodent toothpaste without a desensitizing agent
Number of subjects: 30
Study: 20974325

Group type: EXPERIMENTAL
Intervention: Test tablet (20 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Test capsule (20 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Reference tablet (20 mg)
Number of subjects: 21
Study: 18577912

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 60
Study: 16649836

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12490494

Group type: EXPERIMENTAL
Intervention: Interactive radiofrequency ablation
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard radiofrequency ablation
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Power rolloff achieved
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: No power rolloff
Number of subjects: 97
Study: 10228298

Group type: EXPERIMENTAL
Intervention: Soy formula (579 31 mL/d)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Soy allergy determination
Number of subjects: 93

Group type: COMPARATOR
Intervention: Soy formula
Number of subjects: 93
Study: 8604728

Group type: EXPERIMENTAL
Intervention: Subconjunctival 5‐fluorouracil injections after trabeculectomy
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard filtering surgery (trabeculectomy alone)
Number of subjects: 213
Study: 1778087

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg) - Spironolactone (100 mg) formulation 1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide (20 mg) - Spironolactone (100 mg) formulation 2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pharmacodynamic parameters
Number of subjects: 12
Study: 7376041

Group type: EXPERIMENTAL
Intervention: 25% albumin
Number of subjects: 11

Group type: COMPARATOR
Intervention: lactated Ringer's solution
Number of subjects: 11
Study: 30249374

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg/day) for 2 weeks after surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 2 weeks after surgery
Number of subjects: 100
Study: 27921185

Group type: COMPARATOR
Intervention: MTX + placebo
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MTX + adalimumab
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: HBL6months
Number of subjects: 180
Study: 25818679

Group type: EXPERIMENTAL
Intervention: Atenolol or Lisinopril
Number of subjects: 179
Study: 24212988

Group type: EXPERIMENTAL
Intervention: Bio‐Gen with connective tissue
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bio‐Gen with Biocollagen
Number of subjects: 24
Study: 21357307

Group type: EXPERIMENTAL
Intervention: PSA testing among men aged 40-54 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA testing among men aged 55-74 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PSA testing among men older than 75 years
Number of subjects: 0
Study: 20093332

Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (APG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional wound treatment (Control)
Number of subjects: 44
Study: 17141582

Group type: EXPERIMENTAL
Intervention: Buprenorphine (Bu)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norbuprenorphine (norBu)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method validation
Number of subjects: 0
Study: 15023578

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measuring oxyhemoglobin concentrations during word fluency and finger tapping tasks.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Near-infrared spectroscopy (NIRS) measuring oxyhemoglobin concentrations during finger tapping task.
Number of subjects: 39
Study: 11374599

Group type: EXPERIMENTAL
Intervention: 1 mg of oral lorazepam the night before surgery and 5 mg of intramuscular midazolam on the morning of surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo the night before surgery and on the morning of surgery
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 70
Study: 9040266

Group type: EXPERIMENTAL
Intervention: Collagen plug (Vasoseal)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 62
Study: 8124144

Group type: EXPERIMENTAL
Intervention: Low serum cholesterol concentration (below 5 mmol/l)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Randomised trials (specific treatments for lowering cholesterol)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Community cohorts with low cholesterol
Number of subjects: 687
Study: 3300383

Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 doses)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Mezlocillin (2 doses)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mezlocillin (both doses)
Number of subjects: 107
Study: 31549208

Group type: EXPERIMENTAL
Intervention: MSC implantation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MSC implantation with allogenic cartilage
Number of subjects: 80
Study: 30309244

Group type: EXPERIMENTAL
Intervention: TPH2 rs4570625 (T-allele carriers: G/T or T/T genotypes)
Number of subjects: 185

Group type: COMPARATOR
Intervention: G/G homozygotes
Number of subjects: 185
Study: 28489001

Group type: EXPERIMENTAL
Intervention: Noradrenergic blockade (40 mg propranolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine D2/3 receptor blockade (400 mg amisulpride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25968968

Group type: EXPERIMENTAL
Intervention: Home intervention system (HIS, OPTILOGG(®)) with a tablet computer and weight scale
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard HF information only (Control Group)
Number of subjects: 82
Study: 22966986

Group type: EXPERIMENTAL
Intervention: ABT-102 (2, 6, 18, 30 and 40 mg single dose; 2, 4 and 8 mg twice daily for 7 days; 1, 2 and 4 mg twice daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ABT-102
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 21242462

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 36
Study: 18992984

Group type: EXPERIMENTAL
Intervention: Guidelines 2005
Number of subjects: 40

Group type: COMPARATOR
Intervention: Guidelines 2000
Number of subjects: 40
Study: 16808774

Group type: EXPERIMENTAL
Intervention: Personalized health planning (PHP)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 154
Study: 14971987

Group type: EXPERIMENTAL
Intervention: Specific performance feedback
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: General information
Number of subjects: 32
Study: 11720142

Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy with duodenal partition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antrectomy
Number of subjects: 30
Study: 8988926

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (15 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120